Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
NICORETTE is a nicotine polacrilex lozenge approved by the FDA as a cholinergic nicotinic agonist for nicotine replacement therapy. It delivers nicotine orally via a troche/lozenge formulation to reduce cravings and withdrawal symptoms in patients attempting to quit smoking. The drug acts by stimulating nicotinic acetylcholine receptors, providing a less harmful alternative to tobacco smoke.
With LOE approaching in 2.8 years, the NICORETTE team is likely consolidating focus on brand loyalty and lifecycle extension rather than growth initiatives.
Cholinergic Nicotinic Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers
Clinical Study to Assess Bioequivalence Between Nicorette Extra Mint Gum and Nicorette® Mint Gum in Healthy Smokers
"EASY EFFECTIVE SMOKELESS" With NICORETTE®
Bioequivalence Between an Oral Nicotine Replacement Product and Nicorette® Gum
Evaluation of the Safety Profile, Quit and Reduction Rate After Nicorette® Gum and Patch Treatment
Worked on NICORETTE at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
Working on NICORETTE offers exposure to mature-market brand management and OTC portfolio strategy within GSK's consumer health division. Career progression emphasizes commercial acumen, defensive strategy, and lifecycle optimization rather than novel product development.